ide-cel
1 abstract
Abstract
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.Org: Bristol Myers Squibb, Mayo Clinic, Lille University Hospital, H. Lee Moffitt Cancer Center and Research Institute,